ERBB2 and neoplasm: Post-treatment immunoblot analysis of the tumors revealed trastuzumab-induced dramatic reduction in p-HER2 levels only in the H2-WT tumor group, with no effect observed in S310F and P523S tumor groups (Fig. 6G).